Pharmacology of Cancer Chemotherapy (Cytotoxic Drugs)

Introduction/Overview

Anticancer cytotoxic drugs constitute a cornerstone of modern oncology practice. These agents exert their therapeutic effects by targeting rapidly dividing malignant cells, thereby reducing tumor burden and improving clinical outcomes. Their use, however, is accompanied by significant toxicity, necessitating a thorough understanding of their pharmacology among clinicians and pharmacists. This monograph aims to provide a detailed synthesis of the pharmacodynamic and pharmacokinetic properties of cytotoxic chemotherapy, delineate clinical applications, elucidate adverse effect profiles, and highlight considerations for special populations.

Learning Objectives

• Identify the principal classes of cytotoxic chemotherapy agents and their chemical classifications.
• Describe the molecular mechanisms underlying the antitumor actions of key drug families.
• Summarize the absorption, distribution, metabolism, and excretion characteristics of representative agents.
• Recognize common and serious adverse effects, including black‑box warnings, associated with cytotoxic therapy.
• Apply knowledge of drug interactions and special patient factors to optimize chemotherapy regimens.

Classification

Drug Classes and Categories

Cytotoxic chemotherapy agents are traditionally grouped by their mechanism of action and chemical structure. The major categories include: alkylating agents, antimetabolites, mitotic inhibitors, topoisomerase inhibitors, and others such as platinum compounds and proteasome inhibitors. Each class encompasses multiple agents that share a common pharmacological target.

Chemical Classification

Within each pharmacological class, agents can be further classified by their chemical scaffold. For instance, alkylating agents may be bifunctional (e.g., nitrogen mustards) or monofunctional (e.g., nitrosoureas). Antimetabolites are divided into pyrimidine analogues (e.g., 5‑fluorouracil), purine analogues (e.g., cytarabine), and folate analogues (e.g., methotrexate). Mitotic inhibitors comprise microtubule stabilizers (taxanes) and destabilizers (vinca alkaloids). Topoisomerase inhibitors are categorized by the specific topoisomerase targeted: topoisomerase I (e.g., irinotecan) and topoisomerase II (e.g., doxorubicin). Platinum compounds (e.g., cisplatin) contain a central platinum atom coordinated with ligands that influence reactivity and cellular uptake. Proteasome inhibitors (e.g., bortezomib) target the 20S proteasome complex, leading to apoptosis in plasma cells.

Mechanism of Action

Alkylating Agents

Alkylating agents introduce alkyl groups into DNA strands, generating cross‑links that inhibit replication and transcription. The formation of monoadducts and interstrand cross‑links ultimately triggers apoptosis. The DNA damage response activates p53‑dependent pathways, resulting in cell cycle arrest and apoptosis.

Antimetabolites

Antimetabolites structurally resemble endogenous nucleotides or folate, thereby competitively inhibiting enzymes involved in nucleotide synthesis. For example, 5‑fluorouracil is metabolized to fluorodeoxyuridine monophosphate, which inhibits thymidylate synthase, reducing dTMP availability and impairing DNA synthesis. Purine analogues such as cytarabine are incorporated into DNA, causing chain termination. Folate analogues like methotrexate inhibit dihydrofolate reductase, depleting tetrahydrofolate required for purine and thymidylate synthesis.

Mitotic Inhibitors

Microtubule stabilizers (e.g., paclitaxel) bind to β‑tubulin subunits, promoting polymerization and preventing depolymerization, which arrests cells in the metaphase of mitosis. Microtubule destabilizers (e.g., vincristine) bind to tubulin and inhibit polymerization, also causing metaphase arrest. The mitotic arrest triggers apoptosis through activation of the spindle assembly checkpoint.

Topoisomerase Inhibitors

Topoisomerase I inhibitors, such as irinotecan, form covalent complexes with topoisomerase I and DNA, stabilizing the cleavable complex and preventing re-ligation of single‑strand breaks. This leads to accumulation of DNA single‑strand breaks, which are subsequently converted to double‑strand breaks during replication. Topoisomerase II inhibitors, including anthracyclines (e.g., doxorubicin), stabilize the topoisomerase II–DNA cleavage complex, preventing DNA re-ligation and resulting in double‑strand breaks.

Platinum Compounds

Platinum agents, such as cisplatin, form intra‑ and inter‑strand DNA cross‑links by coordinating with nucleophilic sites on guanine bases. The cross‑links distort the DNA helix, impeding repair and replication. The resulting DNA damage activates apoptotic pathways, including p53 and caspase activation.

Proteasome Inhibitors

Proteasome inhibitors, for instance bortezomib, bind to the proteolytic sites of the 20S proteasome, preventing degradation of ubiquitinated proteins. The accumulation of misfolded proteins induces endoplasmic reticulum stress and activates the unfolded protein response, culminating in apoptosis, particularly in plasma cells.

Pharmacokinetics

Absorption

Most cytotoxic agents are administered intravenously to achieve predictable bioavailability. Oral agents such as capecitabine are prodrugs that undergo first‑pass metabolism to active metabolites (e.g., 5‑fluorouracil). Oral bioavailability varies widely, from ≤10 % for agents with extensive first‑pass metabolism to >60 % for agents with minimal hepatic metabolism.

Distribution

Distribution is characterized by plasma protein binding, tissue penetration, and blood‑brain barrier permeability. Highly protein‑bound drugs (e.g., paclitaxel, 93 %) exhibit limited free drug concentration, whereas agents with moderate binding (e.g., methotrexate, 80 %) have greater free fractions. Lipophilic agents readily cross the blood‑brain barrier, whereas hydrophilic agents are largely excluded. Volume of distribution (V_d) ranges from ≈0.4 L/kg for hydrophilic agents to >10 L/kg for lipophilic agents such as paclitaxel.

Metabolism

Metabolic pathways include phase I oxidative reactions (CYP450 enzymes) and phase II conjugation (glucuronidation, sulfation). For example, irinotecan is converted by carboxylesterase to SN-38, its active metabolite; SN-38 is inactivated by UGT1A1 via glucuronidation. Doxorubicin undergoes hepatic oxidation by CYP3A4 to doxorubicinol, a less active metabolite. The metabolic rate influences half‑life and dosing intervals.

Excretion

Renal excretion predominates for hydrophilic metabolites; e.g., methotrexate is cleared via glomerular filtration and tubular secretion. Hepatic excretion via bile is significant for lipophilic agents (e.g., paclitaxel). The renal clearance (CL_r) of methotrexate is typically ≈1 L/h in adults, necessitating dose adjustment in renal impairment. Clearance (CL) is calculated as CL = Dose ÷ AUC, providing a basis for dose individualization.

Half‑Life and Dosing Considerations

Elimination half‑life (t_1/2) varies among agents: cisplatin t_1/2 ≈ 30 min (distribution) and 20 h (elimination); doxorubicin t_1/2 ≈ 20 h; paclitaxel t_1/2 ≈ 25 h. The dosing schedule is influenced by the drug’s half‑life, toxicity profile, and therapeutic window. For example, 5‑fluorouracil is often given as continuous infusion to maintain steady‑state plasma levels and reduce peak‑related toxicity. Dose adjustments are commonly required based on laboratory parameters (e.g., neutrophil count, creatinine clearance) and patient factors.

Therapeutic Uses/Clinical Applications

Approved Indications

Cytotoxic agents are licensed for a broad spectrum of malignancies:

• Alkylating agents: cyclophosphamide for breast cancer, myeloma; chlorambucil for chronic lymphocytic leukemia.
• Antimetabolites: 5‑fluorouracil for colorectal and gastric cancers; methotrexate for acute lymphoblastic leukemia and metastatic breast cancer; cytarabine for acute myeloid leukemia.
• Mitotic inhibitors: paclitaxel for ovarian and breast cancers; vincristine for neuroblastoma and acute lymphoblastic leukemia.
• Topoisomerase inhibitors: doxorubicin for breast and ovarian cancers; irinotecan for metastatic colorectal cancer.
• Platinum compounds: cisplatin for testicular and ovarian cancers; carboplatin for ovarian and non‑small cell lung cancers.
• Proteasome inhibitors: bortezomib for multiple myeloma.

Off‑Label Uses

Clinicians frequently employ cytotoxic agents off‑label to manage refractory or rare cancers. Examples include the use of gemcitabine for pancreatic and bladder cancers, and the use of etoposide for small cell lung cancer in patients unsuitable for platinum therapy. Off‑label use is guided by emerging evidence, expert consensus, and individual patient considerations.

Adverse Effects

Common Side Effects

• Myelosuppression: neutropenia, anemia, thrombocytopenia; frequently the dose‑limiting toxicity.
• Gastrointestinal toxicity: mucositis, nausea, vomiting, diarrhea; mitigated by antiemetics and dose modification.
• Dermatologic reactions: alopecia, skin rash, nail changes; severity varies with agent.
• Neurotoxicity: peripheral neuropathy (vincristine, paclitaxel), cerebellar dysfunction (oxaliplatin).

Serious/ Rare Adverse Reactions

• Cardiotoxicity: doxorubicin can cause irreversible left ventricular dysfunction with cumulative dose exceeding 550 mg/m².
• Hepatotoxicity: high‑dose cisplatin may induce hepatic sinusoidal obstruction syndrome.
• Pulmonary toxicity: bleomycin-associated interstitial pneumonitis.
• Infusional reactions: anaphylactoid reactions to paclitaxel formulations containing Cremophor EL.

Black‑Box Warnings

• Carcinogenesis: alkylating agents and platinum compounds carry warnings for secondary malignancies due to DNA cross‑linking.
• Cardiotoxicity: anthracyclines’ cumulative dose limits are emphasized.
• Infusional reactions: paclitaxel’s black‑box warning for hypersensitivity necessitates premedication.

Drug Interactions

Major Drug‑Drug Interactions

• Chemotherapeutic agents + CYP450 inhibitors/inducers: irinotecan clearance is reduced by strong CYP3A4 inhibitors (ketoconazole), increasing toxicity; conversely, rifampin induces UGT1A1, lowering SN‑38 levels.
• Antimetabolites + folate antagonists: methotrexate nephrotoxicity is potentiated by NSAIDs and diuretics.
• Proteasome inhibitors + P‑gp inhibitors: bortezomib exposure increases with verapamil, a P‑gp inhibitor.
• Concomitant myelosuppressive agents: combined use of cyclophosphamide and fludarabine may exacerbate neutropenia.

Contraindications

• Paclitaxel: hypersensitivity to Cremophor EL or polysorbate 80.
• Cisplatin: severe renal impairment (creatinine clearance <30 mL/min) without adequate hydration.
• Bleomycin: preexisting pulmonary disease or age >70 years increases risk of pneumonitis.

Special Considerations

Use in Pregnancy/Lactation

Most cytotoxic agents are teratogenic and contraindicated during pregnancy. Agents such as methotrexate and doxorubicin are associated with spontaneous abortion and congenital malformations. Lactation should be withheld during therapy, as drug excretion into breast milk is significant for many agents.

Pediatric/Geriatric Considerations

In pediatric populations, pharmacokinetics differ due to higher metabolic rates and variable organ maturation. Dose adjustments are guided by body surface area and age‑specific pharmacokinetic studies. In geriatrics, reduced renal and hepatic function necessitates dose reduction and close monitoring for toxicity.

Renal/Hepatic Impairment

• Renal impairment: methotrexate requires dose reduction and intensified monitoring of serum creatinine and leucocyte counts.
• Hepatic impairment: doxorubicin clearance decreases by approximately 30 % in Child‑Pugh B; dose adjustment or alternative agents may be preferable.

Summary/Key Points

• Cytotoxic chemotherapy agents are classified by mechanism and chemical structure, influencing both efficacy and toxicity.
• Mechanisms of action involve DNA damage, inhibition of nucleotide synthesis, microtubule disruption, and proteasome inhibition.
• Pharmacokinetic profiles vary markedly; intravenous administration ensures predictable bioavailability, while oral prodrugs rely on first‑pass metabolism.
• Myelosuppression and gastrointestinal toxicity are the most frequent adverse effects; serious sequelae include cardiotoxicity, hepatotoxicity, and secondary malignancies.
• Drug interactions mediated by CYP450 enzymes, UGTs, and transporters can alter exposure and toxicity; careful review of concomitant medications is essential.
• Special populations—pregnancy, lactation, pediatrics, geriatrics, and patients with organ impairment—require dose adjustments and vigilant monitoring.
• Clinical decisions should integrate pharmacodynamic understanding, pharmacokinetic data, and patient‑specific factors to optimize therapeutic outcomes while minimizing harm.

References

1. Chabner BA, Longo DL. Cancer Chemotherapy, Immunotherapy and Biotherapy: Principles and Practice. 6th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.